Neurofibromatosis type 2-related schwannomatosis: an update

Abstract

Neurofibromatosis type 2-related schwannomatosis was first described in 1822. Although it is a different entity with a distinct presentation, it was initially confused with neurofibromatosis type 1 by our forefathers and continues to be confused by clinicians and patients today. Historically, physicians recognized that some patients presented earlier and had more severe phenotypes (Wishart versus Gardner). This has been better understood through genetic and molecular studies, which indicate that the differences are likely related to mosaicism rather than germline mutations. Recently, the nomenclature was changed to Neurofibromatosis type 2-related schwannomatosis, which is more appropriate. Diagnostic criteria have also been modified with the addition of genetic testing results. Treatment remains a conundrum. Historically, surgery has been the mainstay; however, it is risky for large tumors. Vascular endothelial growth factor inhibitors, such as bevacizumab, have been helpful in reducing the size of acoustic schwannomas and have been shown to preserve hearing, along with alleviating other symptoms. However, the medication has clear toxicities, and patients frequently become dependent on treatment or even develop tumor resistance. Numerous trials are ongoing to investigate reduced dosing regimens of vascular endothelial growth factor inhibitors and alternative molecular targets to determine whether the natural progression of the disease can be altered. Gene therapy is on the horizon.

Keywords

Neurofibromatosis type 2 / NF2-related schwannomatosis / schwannomatosis / vestibular schwannoma / meningioma

References

[1] Ahn MS,Lustig LR.The early history of the neurofibromatoses: evolution of the concept of neurofibromatosis type 2.Arch Otolaryngol Head Neck Surg1996;122:1240-9

[2] Brosius S.A history of von Recklinghausen’s NF1.J Hist Neurosci2010;19:333-48

[3] Huson SM. The neurofibromatoses: a pathogenetic and clinical overview. Chapman & Hall Medical; 1994. https://archive.org/details/neurofibromatose0000unse. [Last accessed on 7 Jan 2026].

[4] Mossé A.Tumeurs multiples de l’encephale et de la moelle allongée: neurofibromatosis centrale.Gaz Hebd Med Chir1897;2:789

[5] Ruggieri M,Serra A.Early history of neurofibromatosis type 2 and related forms: earliest descriptions of acoustic neuromas, medical curiosities, misconceptions, landmarks and the pioneers behind the eponyms.Childs Nerv Syst2017;33:549-60

[6] Gardner WJ.Bilateral acoustic neurofibromas: further clinical and pathologic data on hereditary deafness and Recklinghausen’s disease.Arch Neurol Psychiatry1940, 44(1):76-99

[7] Gardner WJ.Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members.Arch Neurol Psychiatry1930;23:266-302

[8] Moyes PD.Familial bilateral acoustic neuroma affecting 14 members from four generations.J Neurosur1968;29:78-82

[9] Young DF,Gardner WJ.Bilateral acoustic neuroma in a large kindred.JAMA1970;214:347-53

[10] Seizinger BR,Gusella JF.Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma.Nature1986;322:644-7

[11] Rouleau GA,Lutchman M.Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.Nature1993;363:515-21

[12] Barker D,Nguyen K.Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17.Science1987;236:1100-2

[13] Trofatter JA,Rutter JL.A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.Cell1993;72:791-800

[14] Hiruta R,Bakhit M.Current progress in genomics and targeted therapies for neurofibromatosis type 2.Fukushima J Med Sci2023;69:95-103 PMCID:PMC10480513

[15] Ghalavand MA,Farhadi M,Garshasbi M.The genetic landscape and possible therapeutics of neurofibromatosis type 2.Cancer Cell Int2023;23:99 PMCID:PMC10204202

[16] Emanuel BS, Zackai EH, Medne L. Emanuel Syndrome. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1263/ [Last accessed on 11 Oct 2025].

[17] Sperfeld AD,Schröder JM,Hanemann CO.Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.Brain2002;125:996-1004

[18] Hexter A,Joe H.Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.J Med Genet2015;52:699-705

[19] Forde C,Rutherford SA.Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.Neuro Oncol2021;23:1113-24 PMCID:PMC8248850

[20] Evans DG,Ramsden RT.Paediatric presentation of type 2 neurofibromatosis.Arch Dis Child1999;81:496-9 PMCID:PMC1718148

[21] Feucht M,Niemüller I.Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders.Acta Ophthalmol2008;86:882-6

[22] Ruggieri M,Polizzi A.Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.Neuropediatrics2005;36:21-34

[23] Pathmanaban ON,Kamaly-Asl ID.Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults.JAMA Neurol2017;74:1123-9 PMCID:PMC5710179

[24] Halliday D,Evans DG.Updated protocol for genetic testing, screening and clinical management of individuals at-risk of NF2-related schwannomatosis.Clin Genet2023;103:540-52

[25] Halliday D,Evans DG.Neurofibromatosis type 2 and related disorders.Curr Opin Oncol2019;31:562-7

[26] Evans DG,King A,Gurusinghe N.Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.Otol Neurotol2005;26:93-7

[27] Evans DG,Shenton A.Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.J Med Genet2007;44:424-8 PMCID:PMC2598002

[28] Plotkin SR,Legius E.International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC)Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation.Genet Med2022;24:1967-7

[29] Jiramongkolchai P,Friedman RA.Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas.Otolaryngol Clin North Am2023;56:533-41

[30] Rowe JG,Walton L,Rodgers J.Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.J Neurol Neurosurg Psychiatry2003;74:1288-93 PMCID:PMC1738689

[31] Tosi U,An A.Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.J Neurooncol2022;156:431-41

[32] Puataweepong P,Ruangkanchanasetr R.Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients.J Neurooncol2023;164:587-95

[33] Bin-Alamer O,Alarifi NA.Stereotactic radiosurgery for vestibular schwannoma in neurofibromatosis type 2: an international multicenter case series of response and malignant transformation risk.Neurosurgery2023;92:934-44

[34] Evans DG,Obholzer R.English Specialist NF2 Research GroupRadiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression.Neurooncol Adv2023;5:vdad025 PMCID:PMC10084499

[35] Ferrara N,Gerber H-P.Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.Nat Rev Drug Discov2004;3,391-400

[36] Plotkin SR,Barker FG.Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.N Engl J Med2009;361:358-67 PMCID:PMC4816642

[37] Plotkin SR,Dhall G.Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.Neuro Oncol2023;25:1498-506

[38] Farschtschi S,Dalchow C,Mautner VF.Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.Eur Arch Otorhinolaryngol2015;272:3857-60

[39] Screnci M,Berton Q,Mom T.Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation.J Clin Med2024;13:7488 PMCID:PMC11642482

[40] Renzi S,Salvador H.Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.Pediatr Blood Cancer2020;67:e28228

[41] Webb MJ,Webb LM.Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.Neuro Oncol Adv2023;5:vdad123 PMCID:PMC10576512

[42] Farschtschi S,Wolf D.Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.Acta Neurol Scand2016;133:475-80

[43] Shi J,Gu R.Integrated analysis of transcriptome and differential methylation of neurofibromatosis type 2 vestibular schwannomas.World Neurosurg2022;157:e66-e76

[44] Tsuchiya T,Teranishi Y.Current molecular understanding of central nervous system schwannomas.Acta Neuropathol Commun2025;13:24 PMCID:PMC11796276

[45] Chang LS,Smith AE.Synodos for NF2 ConsortiumBrigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.PLoS One2021;16:e0252048 PMCID:PMC8282008

[46] Plotkin SR,Nghiemphu PL.INTUITT-NF2 ConsortiumBrigatinib in NF2-related schwannomatosis with progressive tumors.N Engl J Med2024;390:2284-94

[47] Karajannis MA,Hagiwara M.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Neuro Oncol2012;14:1163-70 PMCID:PMC3424212

[48] Plotkin SR,McKenna MJ.Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Neuro Oncol2010;31:1135-43

[49] Goutagny S,Esposito-Farese M.Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.J Neurooncol2015;122:313-20

[50] Karajannis MA,Hagiwara M.Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Neuro Oncol2014;16:292-7 PMCID:PMC3895376

[51] Dombi E,Marcus LJ.Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas.N Engl J Med2016;375:2550-60

[52] Gross AM,Dombi E.Selumetinib in children with inoperable plexiform neurofibromas.N Engl J Med2020;382:1430-42

[53] Weiss BD,Plotkin SR.NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-RELATED PLEXIFORM NEUROFIBROmas.J Clin Oncol2021;39:797-806

[54] Moertel CL,Shuhaiber HH.ReNeu Trial InvestigatorsReNeu Study InvestigatorsReNeu: a pivotal, phase iib trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma.J Clin Oncol2025;43:716-29 PMCID:PMC11825507

[55] Hoy SM.Correction: mirdametinib: first approval.Drugs2025;85:1079 PMCID:PMC12321923

[56] Nagel A,Petrilli A.Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.Oncogene2024;43:921-30 PMCID:PMC10959746

[57] Mendell JR,Shell R.Single-dose gene-replacement therapy for spinal muscular atrophy.N Engl J Med2017;377:1713-22

[58] Nishio H,Saito T,Takeshima Y.Spinal muscular atrophy: the past, present, and future of diagnosis and treatment.Int J Mol Sci2023;24:11939 PMCID:PMC10418635

[59] Hoy SM.Onasemnogene abeparvovec: first global approval.Drugs2019;79:1255-62

[60] Le Guiner C,Montus M.Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.Nat Commun2017;8:16105 PMCID:PMC5537486

[61] Abdul-Razak H,Dickson G.Advances in gene therapy for muscular dystrophies.F1000Res2016;5:2030 PMCID:PMC4991540

[62] Elangkovan N.Gene Therapy for Duchenne Muscular Dystrophy.J Neuromuscul Dis2021;8:S303-16 PMCID:PMC8673537

[63] Prabhakar S,Cheah PS.Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.Mol Ther Methods Clin Dev2022;26:169-80 PMCID:PMC9263409

[64] Yuan R,Wang Y.Gene therapy for neurofibromatosis type 2-related schwannomatosis: recent progress, challenges, and future directions.Oncol Ther2024;12:257-76